Skip to content
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Annual Reports
Investors
Investors
Overview
News & Events
Overview
Company & Partner News
Press Releases
IR Calendar
Email Alerts
Financial Information
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Overview
Charts
Historical Data
IRS Form 8937
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Management Team
Board of Directors
Board Committees
Governance Documents
Annual Reports
Filing Type:
View All
10-K
10-K/A
ARS
Year:
View All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
1998
1996
Date
Form
Description
PDF
XBRL
Pages
03/19/98
10-K
Annual report pursuant to Section 13 and 15(d)
Documents
EX-3.1
EX-3.2
EX-3.4
EX-10.1
EX-10.1A
EX-10.2
EX-10.2A
EX-10.2B
EX-10.3
EX-10.3A
EX-10.3B
EX-10.4
EX-10.4A
EX-10.4B
EX-10.5
EX-10.6
EX-10.7
EX-10.8
EX-10.9
EX-10.11
EX-10.12
EX-10.13
EX-10.14
EX-10.15
EX-10.16
EX-10.17
EX-10.18
EX-10.19
EX-10.19A
EX-10.20
EX-10.21
EX-10.22
EX-10.25
EX-10.26
EX-10.26A
EX-10.27
EX-10.28
EX-10.28A
EX-23.1
EX-27.1
416
Previous
1
2
3
4
Email Alerts
RSS News Feed
Scroll back to top